New Eye Drop for Macular Degeneration Matches Injections
A phase 1 study shows an experimental peptide drop performs on par with current standards in early testing.
Updated on Oct. 27, 2026 in Biotech
Live Poll
Do you believe new medical research leads to better health outcomes for your own healthcare needs?
Researchers presented phase 1 trial results for a novel topical peptide eye drop called CG-P5 designed for wet age-related macular degeneration. The study indicated that the experimental treatment achieved outcomes matching those of the standard injection-based drug aflibercept by day 56.
Why it matters
Up to 40% of patients currently treated for wet AMD do not meet clinical expectations with existing standards of care. A topical alternative could significantly reduce the treatment burden for patients who currently require frequent, invasive injections.
In the 84-day phase 1 study, patients receiving the experimental topical peptide CG-P5 showed improvements in intraretinal fluid and hyperreflective foci matching the performance of 2 mg aflibercept by day 56. Researchers reported zero treatment-related serious adverse events across all trial arms.
The players
Erie Retina Research
A research organization focused on clinical trials and investigations into treatments for retinal diseases.
The details
The study utilized a randomized design to compare the topical peptide CG-P5 against the standard anti-VEGF injection aflibercept, a protein that inhibits the growth of new blood vessels, and a placebo. Researchers monitored pharmacodynamic signals—biological markers indicating how a drug affects the body—to assess the impact of the drops on retinal health. Patients with treatment-experienced wet age-related macular degeneration received the treatments to determine if the topical application could effectively manage fluid and retinal structure stabilization.
Timeline
Day 56: Point at which CG-P5 and aflibercept outcomes were matched.
84 days: Total duration of the phase 1 study.
The Tech Race
The development of CG-P5 marks a departure from the reliance on aflibercept as the primary standard of care for wet AMD. It tracks against the broader biotechnology goal of moving from invasive ocular injections to patient-administered topical treatments.
While promising, the topical peptide CG-P5 remains in the phase 1 research stage and is not currently available for patient use. Future clinical trials must confirm long-term safety and efficacy before this treatment can be considered as a viable replacement for current injection-based AMD therapies.
The takeaway
This phase 1 result establishes that topical peptides can achieve fluid management levels comparable to standard injections over an 84-day period. Readers should monitor future phase 2 and phase 3 trial data to see if these improvements hold for larger patient populations over longer timeframes.
Further reading
For more on advancements in ocular drug delivery, visit our Biotech section.
Live Poll
Do you believe new medical research leads to better health outcomes for your own healthcare needs?
